NEW HAVEN, CT--(Marketwired - September 01, 2016) - Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven") announced today that it has provided Series A financing to Kleo Pharmaceuticals, Inc. ("Kleo") to advance the company's novel Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Recruiting Molecules (SyAMs). The company plans to develop ARMs and SyAMs to treat cancer and infectious diseases. Both companies were spun out of intellectual property arising from Yale University. In addition to the financing, the companies entered into a clinical development master services agreement leveraging the strengths of both companies. Kleo has leading expertise in chemistry discovery, and Biohaven has expertise in pharmaceutical clinical development with its management coming from the pharmaceutical industry including experience at Bristol-Myers Squibb, Pfizer and Alexion. Although the terms of the Series A financing are not disclosed, Biohaven will take a substantial equity stake in Kleo.
Vlad Coric, M.D., CEO of Biohaven, commented, "Strategic investments and partnerships like the one we are embarking upon with Kleo are a highly efficient way for small biotech companies to share risk and create value for its investors. Biohaven is funding a novel and potentially paradigm shifting technology in the cutting edge field of immune-based therapies, and also lending our clinical development expertise to Kleo."
Declan Doogan, M.D., Chairman at Biohaven, added, "We are impressed with the ingenuity of David Spiegel's approach to cancer and infectious disease with the ARMs and SyAMs that were first conceptualized in his lab. Combing the complementary strengths of each company, we believe will result in novel treatment paradigms for patients."
David Spiegel, M.D., PhD., commented, "Biologics have been the gold standard for immunotherapies. With ARMs and SyAMs, we have the opportunity to raise that bar. Our ability to rationally design and synthesize small molecules that emulate the functionality of biologics represents a great advancement in the field. Our molecules are hundreds of times lighter than their biological counterparts and thus may infiltrate tissue more efficiently than large proteins. These small molecules are easier to produce, more tractable to engineer, and non-immunogenic. It's a tremendously exciting time." Dr. Spiegel added, "Combining our expertise in ARMs and SyAMs with Biohaven's investment and development expertise represents an ideal collaboration."
Greg Bailey, M.D., Director at Biohaven, stated, "We are excited about the extraordinary opportunity that Kleo Pharmaceuticals presents. Their unique science with the Biohaven teams' development expertise is a compelling combination. I know our team is focused on translating Kleo's exciting work into the clinic as soon as possible." Dr. Bailey, who was one of the initial financiers of Medivation, added, "The field of immuno-oncology has rapidly been evolving and promises to continue to improve patient outcomes. I've been fortunate to be involved in financing a number of biotech companies and believe that this investment, in particular, can be transformative for Kleo, our patients and to investors."
About Kleo Pharmaceuticals, Inc.
Kleo Pharmaceuticals, Inc. is a biotech company initially formed on the basis of intellectual property from the Spiegel Lab at Yale University. The company was founded by Dr. David Spiegel and Roy Prieb, and is focused on developing a new class of targeted immunotherapies. Yale University previously licensed the PSMA target of ARMs and SyAM to Allied-Bristol Life Sciences, a joint venture between Bristol-Myers Squibb Co. and Allied Minds. The platform technology licensed from Yale University to Kleo involves other targets and intellectual property related to ARMS and SyAMS. Further information regarding Kleo Pharmaceuticals can be found at: http://kleopharmaceuticals.com
About Biohaven Pharmaceutical Holding Company Ltd.
Biohaven is a privately-held biopharmaceutical company with particular expertise in late stage clinical development and has portfolio of multiple late stage drug assets. Biohaven has licensed intellectual property from Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital. The company has advanced multiple candidates into the clinic and plans on pivotal trials beginning late 2016. Biohaven is owned by a group of investors including Yale University, Portage Biotech Inc. (OTC PINK: PTGEF) (CNSX: PBT.U), John W. Childs and other private investors. Further information regarding Biohaven can be found at: http://biohavenpharma.com
This news release includes forward-looking statements within the meaning of the U.S. federal and Canadian securities laws. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management. All statements, other than statements of historical facts, included in this press release regarding the Company's plans and objectives, expectations and assumptions of management are forward-looking statements. The use of certain words, including the words "estimate," "project," "intend," "expect," "believe," "anticipate," "will," "plan," "could," "may" and similar expressions are intended to identify forward-looking statements. The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the Company's forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements including receipt of regulatory approvals and market conditions. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.